Free tool
Oncology stocks
We cover 76 companies grouped under the Oncology theme. The median market value in the group is $625.16M. Across the group, the median move over the past trading day is +2.09%. 64% of the 73 with a 200-day average trade above it. Price change over the past year runs from −22.5% to +208.8% across the middle 80 percent of the group, with a median of +29.3%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
76 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 129.28 EUR | +11.62% | +44.70% | +83.96% | Oct 29, 2026 |
| MRK | Merck & Co., Inc. | $156.45 | +19.65% | +48.06% | +88.17% | Oct 29, 2026 |
| AZN.L | AstraZeneca PLC | 12,110.00 GBP | −6.41% | −10.89% | +1.98% | Oct 30, 2026 |
| AZN | AstraZeneca PLC | $169.66 | +0.01% | −6.39% | +7.60% | Oct 30, 2026 |
| ZYME | Zymeworks Inc. | $27.47 | +19.43% | +3.19% | +88.54% | Nov 5, 2026 |
| IMCR | Immunocore Holdings plc | $37.40 | +10.75% | +10.72% | +14.76% | Nov 5, 2026 |
| DMRA | Damora Therapeutics, Inc. | $30.62 | +4.01% | +40.33% | +800.59% | Nov 5, 2026 |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.41% | −12.36% | −44.50% | Nov 12, 2026 |
| VIR | Vir Biotechnology, Inc. | $10.71 | +21.70% | +80.30% | +144.52% | Nov 4, 2026 |
| INBX | Inhibrx Biosciences, Inc. | $122.72 | +48.84% | +63.54% | +390.10% | Nov 13, 2026 |
| SNDX | Syndax Pharmaceuticals, Inc. | $19.92 | −2.92% | −6.48% | +27.20% | Nov 2, 2026 |
| BCAX | Bicara Therapeutics Inc. | $24.58 | −11.61% | +50.06% | +117.14% | Nov 10, 2026 |
| AVBP | ArriVent BioPharma, Inc. | $31.35 | +3.95% | +50.72% | +62.02% | Nov 16, 2026 |
| REPL | Replimune Group, Inc. | $15.80 | +83.08% | +77.53% | +187.80% | Nov 5, 2026 |
| AKTS | Aktis Oncology, Inc. | $26.69 | +10.24% | +19.15% | +19.15% | Nov 12, 2026 |
| CGEM | Cullinan Therapeutics, Inc. | $22.95 | +31.67% | +126.78% | +200.39% | Nov 5, 2026 |
| IMTX | Immatics N.V. | $9.24 | +7.07% | −11.58% | +76.67% | Nov 17, 2026 |
| GLUE | Monte Rosa Therapeutics, Inc. | $14.56 | −35.46% | −4.90% | +217.21% | Nov 5, 2026 |
| CRVS | Corvus Pharmaceuticals, Inc. | $14.56 | +12.69% | +98.91% | +167.16% | Nov 3, 2026 |
| 2160.T | GNI Group Ltd. | 2,765.00 JPY | +12.58% | +20.74% | +4.54% | Nov 13, 2026 |
| JANX | Janux Therapeutics, Inc. | $18.68 | +19.97% | +36.85% | −18.82% | Nov 5, 2026 |
| KURA | Kura Oncology, Inc. | $13.59 | +33.89% | +31.49% | +77.65% | Nov 3, 2026 |
| CADL | Candel Therapeutics, Inc. | $13.60 | +36.55% | +150.00% | +138.18% | Nov 12, 2026 |
| GERN | Geron Corporation | $1.55 | +4.73% | +17.42% | +9.15% | Nov 4, 2026 |
| EUZ.DE | Eckert & Ziegler SE | 13.65 EUR | −0.29% | −9.06% | −23.06% | Nov 12, 2026 |
| OLMA | Olema Pharmaceuticals, Inc. | $10.91 | −9.16% | −56.84% | +95.17% | Nov 9, 2026 |
| 4587.T | PeptiDream Inc. | 1,135.00 JPY | +22.00% | −29.98% | −28.26% | Nov 11, 2026 |
| RIGL | Rigel Pharmaceuticals, Inc. | $46.75 | +25.03% | +11.76% | +14.75% | Nov 3, 2026 |
| AURA | Aura Biosciences, Inc. | $7.82 | +9.22% | +47.55% | +19.94% | Nov 12, 2026 |
| NVCT | Nuvectis Pharma, Inc. | $25.89 | +32.50% | +204.23% | +298.92% | Nov 3, 2026 |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.37 | +7.09% | −23.76% | −3.50% | Nov 11, 2026 |
| MNPR | Monopar Therapeutics Inc. | $110.82 | +0.44% | +67.88% | +264.30% | Nov 12, 2026 |
| CTMX | CytomX Therapeutics, Inc. | $3.37 | +3.69% | −20.71% | +68.50% | Nov 5, 2026 |
| GUD.TO | Knight Therapeutics Inc. | 9.75 CAD | −0.71% | +64.97% | +49.08% | Nov 5, 2026 |
| EIKN | Eikon Therapeutics, Inc. | $12.55 | +27.02% | −16.33% | −16.33% | Nov 12, 2026 |
| 0QAV.L | Nanobiotix S.A. | 34.51 EUR | −2.83% | +80.19% | +346.30% | Sep 29, 2026 |
| VSTM | Verastem, Inc. | $7.08 | +16.45% | −2.07% | −21.16% | Nov 3, 2026 |
| SGMT | Sagimet Biosciences Inc. | $10.29 | +38.12% | +71.79% | +45.34% | Nov 12, 2026 |
| ARVN | Arvinas, Inc. | $9.60 | +16.79% | −16.30% | +28.34% | Nov 4, 2026 |
| DCTH | Delcath Systems, Inc. | $16.92 | +41.71% | +70.05% | +55.37% | Nov 3, 2026 |
| 0KCS.L | OPKO Health, Inc. | $1.51 | +2.03% | +16.20% | +5.63% | Oct 28, 2026 |
| PRLD | Prelude Therapeutics Incorporated | $6.59 | +69.41% | +141.39% | +418.90% | Nov 11, 2026 |
| CCCC | C4 Therapeutics, Inc. | $4.20 | +16.99% | +117.62% | +66.01% | Nov 5, 2026 |
| 0IL8.L | Kyntra Bio, Inc. | $7.95 | +1.50% | −11.24% | −24.41% | Nov 9, 2026 |
| PBYI | Puma Biotechnology, Inc. | $9.32 | +16.65% | +61.53% | +86.77% | Nov 5, 2026 |
| 0LOV.L | Verastem, Inc. | $7.14 | +3.48% | −1.92% | −21.47% | Nov 3, 2026 |
| CMPX | Compass Therapeutics, Inc. | $2.53 | +21.63% | −51.06% | −16.23% | Nov 5, 2026 |
| FENC | Fennec Pharmaceuticals Inc. | $11.71 | +14.69% | +52.47% | +35.38% | Nov 12, 2026 |
| FHTX | Foghorn Therapeutics Inc. | $6.85 | +31.73% | +31.98% | +30.48% | Nov 5, 2026 |
| PRTC.L | PureTech Health plc | 118.80 GBP | +0.51% | −4.65% | −11.34% | Aug 27, 2026 |
| FRX.TO | Fennec Pharmaceuticals Inc. | 15.49 CAD | +5.73% | +48.80% | +27.38% | Nov 12, 2026 |
| AGEN | Agenus Inc. | $8.36 | +36.38% | +158.82% | +90.43% | Nov 5, 2026 |
| CATX | Perspective Therapeutics, Inc. | $3.29 | +16.67% | +17.92% | −4.91% | Nov 9, 2026 |
| 0XOD.L | UroGen Pharma Ltd. | $46.35 | −1.31% | +105.18% | +136.32% | Nov 5, 2026 |
| BCYC | Bicycle Therapeutics plc | $4.39 | +11.14% | −34.28% | −38.34% | Oct 29, 2026 |
| WHWK | Whitehawk Therapeutics, Inc. | $5.08 | +37.30% | +108.20% | +198.82% | Nov 5, 2026 |
| ALXO | ALX Oncology Holdings Inc. | $2.00 | −0.99% | +73.91% | +81.82% | Nov 6, 2026 |
| MGNX | MacroGenics, Inc. Common Stock | $4.17 | +4.25% | +159.01% | +154.27% | Nov 12, 2026 |
| GLSI | Greenwich LifeSciences, Inc. | $18.59 | +38.32% | −4.52% | +56.35% | Nov 12, 2026 |
| 0IV3.L | Geron Corporation | $1.54 | 0.00% | +16.67% | +8.41% | Nov 4, 2026 |
| PYXS | Pyxis Oncology, Inc. | $3.06 | +5.15% | +166.09% | +120.14% | Nov 2, 2026 |
| IPHA | Innate Pharma S.A. | $2.27 | +28.10% | +24.73% | +1.34% | Sep 17, 2026 |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% | Sep 17, 2026 |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +17.37% | +16.21% | +1.84% | Sep 17, 2026 |
| TARA | Protara Therapeutics, Inc. | $3.97 | −1.73% | −26.21% | +30.16% | Nov 10, 2026 |
| CHRS | Coherus Oncology, Inc. | $1.37 | −6.16% | 0.00% | +17.09% | Nov 5, 2026 |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +4.07% | −17.21% | −24.30% | Aug 27, 2026 |
| 0IMT.L | Photocure ASA | 53.80 NOK | +0.35% | −25.59% | −12.59% | Oct 28, 2026 |
| ADCT | ADC Therapeutics SA | $1.04 | −8.77% | −70.45% | −66.34% | Nov 10, 2026 |
| HURA | TuHURA Biosciences, Inc. | $2.04 | −7.69% | +172.00% | −30.85% | Nov 13, 2026 |
| 0RU5.L | Oncoinvent ASA | 70.20 NOK | −18.37% | +61.75% | +5951.72% | Aug 27, 2026 |
| BDTX | Black Diamond Therapeutics, Inc. | $2.24 | +29.48% | −10.04% | −21.95% | Nov 5, 2026 |
| ANIX | Anixa Biosciences, Inc. | $3.66 | +5.78% | +15.82% | +22.00% | Sep 9, 2026 |
| NTHI | NeOnc Technologies Holdings, Inc. | $4.71 | +36.92% | −46.96% | −18.72% | Nov 12, 2026 |
| HBP.TO | Helix BioPharma Corp. | 1.99 CAD | +38.19% | −17.08% | +35.37% | Oct 29, 2026 |
| ONCY | Oncolytics Biotech Inc. | $0.86 | +7.68% | −12.10% | −12.99% | Nov 16, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.